Study | Country Study period Study design |
Data source | Exposure definition | Non-exposure definition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|---|---|---|---|---|---|---|---|
Beauverd 2016 |
United Kingdom 2013 - 2015 retrospective cohort |
Pregnancies in essential thrombocythemia (ET) women treated with Pegylated interferon alpha-2a (PEG-IFN). |
exposed to other treatment, sick
Previous pregnancies in the same women without use of Pegylated interferon alpha-2a (PEG-IFN). |
during pregnancy (anytime or not specified) | 10 / 9 | Other treatments in control group: low dose aspirin, ow molecular weight heparin (LMWH), IFN. | ||
Demographics, past medical and obstetric history, previous thrombosis and hemorrhage, previous treatment, disease characteristics at diagnosis and during pregnancy were retrospectively extracted from patients’ notes. |
Study | Country Study period Study design |
Data source | Case | Control | Exposition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|
Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;